A Study of Treatment Patterns in HER2-positive Unresectable and Advanced Gastric/ Gastroesophageal Junction Cancer in China
NCT06585501 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 805
Last updated 2025-08-21
Summary
This study will be conducted to retrospectively evaluate the treatment patterns in first-line, second-line, and subsequent lines of therapy for HER2-positive Gastric Cancer/Gastroesophageal Junction Cancer (GC/GEJC) patients.
Conditions
Interventions
- OTHER
-
No drug
This is a non-interventional study and no study drug will be provided.
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-08-15
- Primary Completion
- 2025-07-30
- Completion
- 2025-07-30
Countries
- China
Study Locations
More Related Trials
-
Dual EGFR/HER2 Blockade Combined With Irinotecan for the Treatment of HER2-Positive Metastatic Colorectal Cancer
NCT07059338 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
AI Prediction of Gastric Cancer Response to Neoadjuvant Chemotherapy
NCT06035250 ·Status: RECRUITING
-
Regorafenib Treatment Patterns and Survival Outcomes in Advanced Colorectal Cancer: A Real-world Study
NCT04835324 ·Status: UNKNOWN
-
Real-World Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer
NCT05023720 ·Status: UNKNOWN
-
Extent of Lymph Node Dissection for Advanced Right-Sided Colon Cance
NCT06986538 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer
NCT06210971 ·Status: RECRUITING ·Phase: PHASE2
-
BGT007H Cells for the Treatment of Refractory Digestive System Tumors
NCT06104215 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
RC48 Plus Tislelizumab, Low-dose Capecitabine and Celecoxib for HER2-positive Metastatic Colorectal Cancer
NCT05578287 ·Status: RECRUITING ·Phase: PHASE2
-
The Real Clinical Background of Advanced Colorectal Cancer Treatment Situation Survey
NCT01549067 ·Status: UNKNOWN
-
Bioinformation Therapy for Gastric Cancer
NCT03350477 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
NCT04215510 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
BGT007 Cells for the Treatment of Refractory Digestive System Tumors
NCT06104241 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Chemotherapy Combined With High-dose Radiotherapy for Low Rectal Cancer Using MR Guided Linear Accelerator
NCT05338866 ·Status: ENROLLING_BY_INVITATION
-
Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer
NCT06879197 ·Status: COMPLETED
-
Investigation of Association Between UGT1A1 Polymorphisms and Irinotecan Toxicity in Korean Patients
NCT01271582 ·Status: UNKNOWN ·Phase: PHASE4
-
Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy
NCT05962502 ·Status: RECRUITING ·Phase: PHASE2
-
Short-term and Long-term Outcomes of Colorectal Cancer Treated With Natural Orifice Specimen Extraction Surgery : a National Registry-based Study
NCT06350370 ·Status: RECRUITING ·Phase: NA
-
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
NCT06835179 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma
NCT00658801 ·Status: TERMINATED ·Phase: PHASE1
-
Preoperative Systemic Therapy for Colorectal Cancer Peritoneal Metastases
NCT05353582 ·Status: UNKNOWN ·Phase: PHASE2
-
Validate the Dosimetric Parameters That Correlate With Acute Hematologic Toxicity (HT) in Patients With Rectal Cancer
NCT02630056 ·Status: UNKNOWN
-
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
NCT05785325 ·Status: UNKNOWN ·Phase: PHASE2
-
Genotype-driven Phase I Study of Irinotecan Administered in Neoadjuvant Chemoradiotherapy in Patients With Stage II/III Rectal Cancer
NCT01474187 ·Status: UNKNOWN ·Phase: PHASE1
-
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
NCT03573791 ·Status: RECRUITING
-
Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer
NCT07034742 ·Status: RECRUITING ·Phase: EARLY_PHASE1